LRRK2 and Parkinson disease: Since genetic studies have indicated no association of LRRK2 loss of function alleles with PD, [37] another approach now entering clinical trials is the use of antisense oligonucleotides (ASOs) to reduce the levels of active LRRK2 protein [38,39].